8-K: Invivyd Reports Q2 2026 Growth, Clinical Trials Advance

Invivyd announced second quarter 2026 financial results, highlighting a 21% increase in PEMGARDA net product revenue to $14.3 million and progress in key clinical trials for VYD2311.

Summary

• Invivyd reported $14.3 million in PEMGARDA net product revenue for Q2 2026, a 21% increase compared to $11.8 million in Q2 2025.
• The company completed enrollment in its DECLARATION pivotal clinical trial and the LIBERTY clinical trial, with top-line data anticipated in late Q3 2026.
• Cash and cash equivalents stood at $160.1 million as of June 30, 2026, which is expected to provide runway through the DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311.
• Research and development expenses increased to $29.4 million in Q2 2026 from $9.6 million in Q2 2025, primarily due to clinical trial costs for VYD2311.
• Selling, general, and administrative expenses rose to $29.5 million in Q2 2026 from $16.6 million in Q2 2025, attributed to increased personnel and commercial-related costs.
• Net loss for Q2 2026 was $44.4 million, a significant increase from $14.7 million in Q2 2025.
• Invivyd received twelve months' advanced notice of the termination of the emergency use authorization (EUA) for PEMGARDA, with dialogue ongoing with the FDA.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report. While revenue growth is positive and key clinical trials are progressing, the significant increase in net loss and R&D/SG&A expenses indicate substantial ongoing investment and a widening deficit.

Positives

• PEMGARDA net product revenue grew by 21% to $14.3 million in Q2 2026 compared to $11.8 million in Q2 2025.
• Enrollment is complete for the DECLARATION pivotal clinical trial and the LIBERTY clinical trial.
• The company maintains a strong cash position of $160.1 million as of June 30, 2026, expected to fund operations through key data readouts.
• Positive in vitro neutralization data for PEMGARDA and VYD2311 against SARS-CoV-2 variant BA.3.2.2 (Cicada) was reported.
• Advancement of measles monoclonal antibody candidate VMS063 towards IND readiness in 2H 2026.
• Expectation to advance RSV monoclonal antibody candidate VBY329 towards IND readiness in 2H 2026.

Negatives

• Net loss widened significantly to $44.4 million in Q2 2026 from $14.7 million in Q2 2025.
• R&D expenses more than tripled to $29.4 million in Q2 2026 from $9.6 million in Q2 2025.
• SG&A expenses increased by over 77% to $29.5 million in Q2 2026 from $16.6 million in Q2 2025.
• The emergency use authorization (EUA) for PEMGARDA is scheduled for termination in June 2027, with advanced notice received.
• Net loss per share increased to $0.14 in Q2 2026 from $0.12 in Q2 2025.

Risks

• The emergency use authorization (EUA) for PEMGARDA is scheduled for termination on June 29, 2027.
• Potential emergence of SARS-CoV-2 viral variants with substantially reduced susceptibility to PEMGARDA.
• The DECLARATION pivotal clinical trial is subject to COVID-19 attack rate variability impacting statistical power.
• The DRUMMER pediatric clinical trial for VYD2311 is contingent on the success of the DECLARATION trial.
• The company may require additional financing to meet future operating expenses and capital expenditure requirements.
• Uncertainties related to the regulatory authorization or approval process for VYD2311.
• Potential variability in neutralizing activity of product candidates tested in different assays.

Future Outlook

Top-line data for the DECLARATION and LIBERTY clinical trials are anticipated in late Q3 2026. The company expects its current cash position to fund operations through these readouts and support potential commercial launch readiness for VYD2311. Invivyd also plans to advance VMS063 and VBY329 towards IND readiness in the second half of 2026.

Management Comments

• "With our VYD2311 DECLARATION and LIBERTY clinical trials planned to wrap up in the coming weeks, we are looking forward to the next steps for vulnerable Americans."
• "The public health need for antibody-based protection with attractive safety is enormous, and we are confident that many public health leaders and policy makers in the United States understand the importance of having non-vaccine options available for the American public health."
• "We are pleased with continued growth of PEMGARDA, especially in the face of understandably diminished COVID vaccine utilization."
• "We are pleased with our strong cash position as we approach planned top-line data for our VYD2311 pivotal program later this quarter."
• "We have continued to diligently manage expenses, albeit during a period of critical heavy clinical investment in our pivotal VYD2311 program, which we expect to complete shortly as we move toward potential launch of VYD2311, if approved."

Industry Context

StockSavvy.ai notes that Invivyd's results are being released in a dynamic biopharmaceutical landscape where demand for COVID-19 related products is evolving. The company's focus on antibody-based protection, particularly for immunocompromised individuals and as a potential vaccine alternative, positions it within a niche but critical segment of the infectious disease market. The increasing R&D and SG&A expenses reflect the significant investment required for late-stage clinical development and potential commercialization in this competitive field.

Related Party Transactions

• Includes related-party amounts of $576 in accounts payable and $1,129 in R&D expenses as of June 30, 2026.

Stakeholder Impact

• Shareholders: Increased net loss and expenses may raise concerns about future funding needs and profitability, despite positive clinical trial progress and revenue growth.
• Employees: Continued investment in R&D and commercial readiness may indicate future growth opportunities but also reflects the high-risk nature of drug development.
• Creditors: The company's cash position is expected to provide runway, but significant ongoing expenses could impact future liquidity if milestones are not met or capital is not raised.
• Regulators (FDA): Ongoing dialogue regarding PEMGARDA's EUA termination and the progress of VYD2311 trials are critical for future product approvals and market access.

Next Steps

• Hold an investor call post completion of the DECLARATION pivotal clinical trial.
• Anticipate top-line data from the DECLARATION and LIBERTY clinical trials in late Q3 2026.
• Continue dialogue with the FDA regarding appropriate next steps for PEMGARDA following the notice of EUA termination.
• Advance VMS063 (measles candidate) towards IND readiness in 2H 2026.
• Advance VBY329 (RSV candidate) towards IND readiness in 2H 2026.
• Initiate Phase 2 clinical trial for VYD2311 in Long COVID patients (expected mid-2026).

Key Dates

Recommendation

The company shows positive revenue growth and significant progress in key clinical trials, which are strong positives. However, the substantial increase in net loss and operating expenses, coupled with the impending termination of PEMGARDA's EUA, introduces considerable risk. The current cash position provides a buffer, but the path to profitability and commercial success for VYD2311 remains uncertain and dependent on upcoming clinical data and regulatory approvals. Therefore, a 'hold' recommendation reflects a balanced view of the potential upside and the significant risks involved.

Keywords

COVID-19, monoclonal antibody, pemivibart, VYD2311, clinical trial, financial results, biopharmaceutical, FDA